Pots, houses and metal: technological relations at the Bronze Age tell at Százhalombatta, Hungary

At the Bronze Age tell of Százhalombatta, Hungary, techniques used for making pottery echo those used in other media. Pottery and architecture have a close relationship. Not only were both made of clay, but methods of making pots echo those used for building. Similarly, pottery and metalwork share common themes and technologies for working with clay and bronze. Since choices made by potters are not solely confined to the environment, raw materials and tools, but are also socially and culturally defined, by implication the transfer of know-how must be situated within social networks between people. This paper considers how the identification of technical relationships between different media at Százhalombatta can be used to explore social relations in Bronze Age society, thereby suggesting relationships that work on both technical and social levels

The soluble CTLA-4 receptor and its role in autoimmune diseases: an update

CTLA-4, initially described as a membranebound molecule, is a costimulatory receptor transducing a potent inhibitory signal. Increasing evidence shows the CTLA-4 gene to be an important susceptibility locus for autoimmune endocrinopathies and other autoimmune disorders. A soluble form of cytotoxic T-lymphocyte-associated antigen-4 (sCTLA-4) has been established and shown to possess CD80/CD86 binding activity and in vitro immunoregulatory functions. sCTLA-4 is generated by alternatively spliced mRNA. Whereas low levels of sCTLA-4 are detected in normal human serum, increased serum levels are observed in several autoimmune diseases (e.g. Graves’ disease, myasthenia gravis, systemic lupus erythematosus, type 1 diabetes, systemic sclerosis, coeliac disease, autoimmune pancreatitis and primary biliary cirrhosis). The biological significance of increased sCTLA-4 serum levels is not fully clarified yet. On the one hand, it can be envisaged that sCTLA-4 specifically inhibits early T-cell activation by blocking the interaction of CD80/CD86 with the costimulatory receptor CD28. On the other hand, higher levels of sCTLA-4 could compete for the binding of the membrane form of CTLA-4 with CD80/CD86 in the later phases of T-lymphocyte activation, causing a reduction in inhibitory signalling. This double-edged nature of sCTLA-4 to block the binding of CD28 to CD80/CD86 may result in different outcomes during the clinical course of an autoimmune disease